Morgan Stanley
AFJK

Morgan Stanley’s Aimei Health Technology Co AFJK Stock Holding History

Morgan Stanley’s Portfolio AFJK Stock Details AFJK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3K Sell
43
-7
-14% -$282 ﹤0.01% 7476
2026
Q1 		$1.23K Buy
50
+18
+56% +$792 ﹤0.01% 7401
2025
Q4 		$2.05K Buy
32
+4
+14% +$87 ﹤0.01% 7238
2025
Q3 		$317 Buy
28
+5
+22% +$56 ﹤0.01% 7545
2025
Q2 		$254 Buy
23
+9
+64% +$100 ﹤0.01% 7539
2025
Q1 		$154 Buy
+14
New +$152 ﹤0.01% 7505

Other funds holding AFJK

FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's AFJK Position: Q2 2026 in Review

Morgan Stanley reduced its Aimei Health Technology Co (AFJK) stake by 14% in Q2 2026, selling an estimated $282 and leaving 43 shares worth $1.3K. The position accounts for ﹤0.01% of the portfolio, ranked #7476.

Morgan Stanley first reported a position in AFJK in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.05K in Q4 2025. 7 funds tracked by Wall St. Rank hold AFJK as of Q2 2026.

  • Morgan Stanley held 43 shares of Aimei Health Technology Co worth $1.3K as of Q2 2026.
  • Morgan Stanley sold 7 Aimei Health Technology Co shares in Q2 2026, an estimated $282.
  • Aimei Health Technology Co made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7476 holding.
  • Morgan Stanley first reported a position in Aimei Health Technology Co in Q1 2025 and has held it in 6 quarters since.
  • Morgan Stanley's Aimei Health Technology Co position peaked at $2.05K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Aimei Health Technology Co as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.